PFG Investments LLC Increases Stock Position in Eli Lilly and Company $LLY

Key Points

• PFG Investments LLC increased its stake in Eli Lilly by 11.9% in the first quarter, buying 1,028 additional shares and bringing its total holdings to 9,644 shares worth about $8.87 million.
• Institutional ownership in Eli Lilly remains very high at 82.53%, and several other hedge funds and investors also added or initiated positions in the stock.
• Analysts remain broadly bullish on LLY, with a Moderate Buy consensus and an average price target of $1,235.07, supported by strong earnings and optimism around its GLP-1 drug pipeline.

PFG Investments LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 11.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,644 shares of the company's stock after buying an additional 1,028 shares during the period. PFG Investments LLC's holdings in Eli Lilly and Company were worth $8,870,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Maryland Capital Advisors Inc. purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at $25,000. Osbon Capital Management LLC purchased a new stake in Eli Lilly and Company during the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after purchasing an additional 16 shares in the last quarter. Basso Capital Management L.P. bought a new position in Eli Lilly and Company in the 4th quarter worth about $30,000. Finally, Maseco LLP grew its holdings in Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after buying an additional 28 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Coverage highlighted Eli Lilly as a leader in GLP-1 therapies with an expanding pipeline and diversified growth strategy, reinforcing the bull case despite the stock’s premium valuation. Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
• Positive Sentiment: Shares were lifted by optimism around GLP-1 Medicare inclusion and strong reported results, which investors view as supportive of continued demand and revenue growth. Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results
• Positive Sentiment: Another bullish note argued that artificial intelligence could become a long-term growth tailwind for Eli Lilly by improving drug development and operational efficiency. AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why
• Positive Sentiment: Repeated mentions in pharmaceutical and medical stock roundups suggest Lilly remains one of the sector’s preferred large-cap names for investors seeking growth exposure. Pharmaceutical Stocks To Follow Now - July 2nd
• Positive Sentiment: Additional commentary pointed to Lilly’s appeal to long-term, high-conviction investors, including billionaire hedge fund manager Cliff Asness, adding to the stock’s credibility as a favored healthcare holding. Is Eli Lilly (LLY) One of Billionaire Cliff Asness’ Best Healthcare Stock Picks ?
• Neutral Sentiment: One item noted a leadership change at Lilly Korea, which appears operationally routine and unlikely to move the stock on its own. Eli Lilly Korea names Komasu Seiya new representative
• Neutral Sentiment: General industry pieces about pharmaceutical growth and the sector’s $2 trillion sales trajectory are supportive of sentiment, but they do not add a specific new catalyst for Lilly. Can pharma sustain its $2T trajectory?

Analyst Ratings Changes

A number of research firms recently weighed in on LLY. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a report on Monday, June 8th. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Friday, June 5th. Jefferies Financial Group lifted their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a research note on Tuesday, June 9th. HSBC cut Eli Lilly and Company from a "hold" rating to a "reduce" rating and reduced their target price for the stock from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average target price of $1,235.07.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,208.37 on Friday. The firm's fifty day moving average price is $1,065.45 and its 200-day moving average price is $1,028.14. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock has a market cap of $1.14 trillion, a P/E ratio of 42.93, a price-to-earnings-growth ratio of 1.51 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,238.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. During the same period in the previous year, the business earned $3.34 earnings per share. The firm's quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 35.74 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company's dividend payout ratio is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.